Effects of Thymoquinone and Cisplatin on C-MYC, KRAS, p53 and EGFR Gene Expression in Lung Cancer Cell Lines
Journal of Cancer and Tumor International,
Lung cancer is one of the most common causes of death.It is known that genetic reasons in its etiology.Lung cancer has been shown to be associated with the EGFR,P53,KRAS and c-MYC genes.Thymoquinone is an antitumoral and antineoplastic bioactive substance procured from Nigella sativa plant.Cisplatin is a frequently used chemotherapeutic agent in the treatment of lung cancer.Our study has been conducted to examine the effects of Tq and Cis on gene expressions on lung cancer cell lines.Potential effects of Tq and Cis on A549,HTB54, CRL5820 and BEAS2B cell lines and cell viability using MTT has been evaluated.Cell culture has been effectuated with RPMI supplemented with 10% FBS,1% antibiotic and DMEM(37°C, %5 CO2).Cells were cultured for 24 h in 96 well plates(2500/ml cells) 10% FBS RPMI appropriate medium.The cells have been exposured 100 μM Tq and 200 μM Cis for 4h under incubation conditions.DMSO has been used for negative control.RT PCR has been conducted using SYBR Green qPCR Master Mix(reference gene GAPDH).As a result, p53 gene suppression has been shown in lung adenocarcinoma with Tq and Cis and epidermoid carcinoma with Cis only.EGFR gene suppression has been shown in lung adenocarsinoma with Tq only and epidermoid carcinoma with Cis only.C-MYC gene suppression has been shown in lung adenocarsinoma with both substances(more at Tq).It has been shown that KRAS gene suppression does not occur in any cell line.In addition, it has been shown that no gene expression is suppressed after Tq and cis exposure in the mesothelioma cell line.
- lung cancer
- gene expression
- cell lines
How to Cite
Gibbons DL, Byers AL, Kurie MJ. Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014;12(1):3-13.
Chanvorachote P, Sriratanasak N, Nonpanya N. C-myc contributes to malignancy of lung cancer: A potential anticancer drug target. Anticancer Res. 2020;40(2):609-618.
Westcott Peter MK, To MD. The genetics and biology of KRAS in lung cancer. Chin J Cancer. 2013;32(2):63-70.
Jin R, Peng L, Shou J, et al. EGFR-mutated squamous cell lung cancer and Its association with outcomes. Front. Oncol. 2021;11:1-10.
Roepke M, Dıestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A, Schneıder-Stock R, Galı-Muhtasıb H. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther. 2007;6(2): 160-9.
Tasdemir D. et al. Synthesis, molecular modeling, and biological evaluation of novel chiral thiosemicarbazone derivatives as potent anticancer agents. Chirality. 2015;27(2):177-188.
Jia J. et al. Cholesterol metabolism promotes B-cell positioning during immune pathogenesis of chronic obstructive pulmonary disease. EMBO Mol Med. 2018;10(5):e8349.
Hussain SP, Harris CC. Molecular epidemiology and carcinogenesis: Endogenous and exogenous carcinogens. Mutation Research. 2000;311-322.
Ciardello F. Epidermal growth factor receptor tyosine kinase inhibitors as anticancer agents. Drugs. 2000;60(1):25-32.
Kılıçoğlu CE. Prognostic value of expression of epidermal growth factor in non-small cell lung cancer. Gazi University Faculty of Medicine,Specialization Thesis; 2002.
Bethune G, Bethune D, Ridgway N, et al. Epidermal Growth Factor Receptor (EGFR) in lung cancer: An overview and update. J Thorac Dis. 2010;2(1):48- 51.
Barr LF, Campbell SE, Diette GB, et al. c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression. Tumor Biology. 2000;60(1): 143-149.
Seo AN, Yang JM, Kim H, et al. Clinicopathologic and prognostic significance of c-Myc copy number gain in lung adenocarcinomas. British J Cancer. 2014;110:2688-2699.
Biernacka A, Tsongalis PD, Peterson JD, et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016;209:195-198.
Xie M, Xu X, Fan Y. KRAS-mutant non-small cell lung cancer: An emerging promisingly treatable subgroup. Front. Oncol. 2021;11:1-11.
Abstract View: 37 times
PDF Download: 20 times